<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126200</url>
  </required_header>
  <id_info>
    <org_study_id>208887</org_study_id>
    <nct_id>NCT04126200</nct_id>
  </id_info>
  <brief_title>Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)</brief_title>
  <official_title>A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with&#xD;
      multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC)&#xD;
      containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized,&#xD;
      open-label, platform study designed to evaluate the effects of belantamab mafodotin in&#xD;
      combination with other anti-cancer drugs in participants with relapsed/refractory multiple&#xD;
      myeloma. The Platform design incorporates a single master protocol, where multiple treatment&#xD;
      combinations, as sub-studies, will be evaluated simultaneously.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">February 23, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There will be a dose exploration (DE) phase which will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with other anti-cancer treatments. A recommended Phase 2 dose (RP2D) for each combination treatment will be identified based on the safety and preliminary efficacy in DE. This will be followed by a cohort expansion (CE) phase which will evaluate the clinical activity of the combination treatment in comparison to belantamab mafodotin monotherapy in additional participants.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DE Phase: Number of participants achieving dose limiting toxicities (DLT)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>An event is considered to be a dose DLT if the event occurs within the first 21 days of treatment and meets the dose limiting toxicity criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>AEs and SAEs will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DE Phase: Number of participants with abnormality in vital signs</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CE Phase: Number of participants achieving Overall Response Rate (ORR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>ORR is defined as the percentage of participants with a Partial response (PR) or better, according to the International Myeloma Working Group (IMWG) Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DE Phase: Number of participants achieving ORR</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>ORR is defined as the percentage of participants with PR or better, according to the IMWG Response Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants achieving Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>CBR is defined as the percentage of participants with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants achieving Partial Response</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants with PR according to IMWG criteria will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants achieving Very Good Partial Response (VGPR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants with VGPR according to IMWG criteria will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants achieving Complete Response (CR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Participants with CR according to IMWG criteria will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants achieving stringent Complete Response (sCR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Participants with sCR according to IMWG criteria will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of belantamab mafodotin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of GSK3174998.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: feladilimab concentration when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of feladilimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of nirogacestat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of dostarlimab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples will be collected for concentrations of isatuximab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Concentration of anti-drug antibodies (ADAs) against belantamab mafodotin when administered in combination with anti-cancer treatments</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples for concentrations for ADAs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples for concentrations for ADAs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples for concentrations for ADAs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples for concentrations for ADAs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood samples for concentrations for ADAs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants with adverse events of special interest (AESI)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>AESIs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DE Phase and CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Ophthalmic examination will assess abnormal findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants achieving Progression-free survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Duration of response (DoR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Time to response (TTR)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants achieving Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>OS is defined as the time from randomization until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants with AEs and SAEs</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>AEs and SAEs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants with AEs leading to discontinuation</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants with AEs leading to discontinuation will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants with dose reduction or delay</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants with dose reduction or delay will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants with abnormality in vital signs</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, temperature, respiratory rate and pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin monotherapy cohort expansion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+ nirogacestat cohort expansion(Sub-study 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+ dostarlimab cohort expansion(Sub-study 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belantamab mafodotin+ isatuximab cohort expansion(Sub-study 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>Belantamab mafodotin will be administered</description>
    <arm_group_label>Belantamab mafodotin monotherapy cohort expansion</arm_group_label>
    <arm_group_label>Belantamab mafodotin+ dostarlimab cohort expansion(Sub-study 4)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+ isatuximab cohort expansion(Sub-study 5)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+ nirogacestat cohort expansion(Sub-study 3)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3174998</intervention_name>
    <description>GSK3174998 will be administered</description>
    <arm_group_label>Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Feladilimab</intervention_name>
    <description>feladilimab will be administered.</description>
    <arm_group_label>Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nirogacestat</intervention_name>
    <description>Nirogacestat will be administered</description>
    <arm_group_label>Belantamab mafodotin+ nirogacestat cohort expansion(Sub-study 3)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dostarlimab</intervention_name>
    <description>Dostarlimab will be administered.</description>
    <arm_group_label>Belantamab mafodotin+ dostarlimab cohort expansion(Sub-study 4)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Isatuximab will be administered</description>
    <arm_group_label>Belantamab mafodotin+ isatuximab cohort expansion(Sub-study 5)</arm_group_label>
    <arm_group_label>Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 years of age inclusive or older, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants must have histologically or cytologically confirmed diagnosis of Multiple&#xD;
             Myeloma (MM), as defined by the IMWG.&#xD;
&#xD;
          -  Participants having at least 3 prior lines of prior anti-myeloma treatments including&#xD;
             an immunodilating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal&#xD;
             antibody.&#xD;
&#xD;
          -  Participants with a history of autologous stem cell transplant are eligible for study&#xD;
             participation when, transplant was &gt;100 days prior to study enrolment and with no&#xD;
             active infection(s).&#xD;
&#xD;
          -  Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1,&#xD;
             unless ECOG less than equal to (&lt;=)2 is due solely to skeletal complications and/or&#xD;
             skeletal pain due to MM.&#xD;
&#xD;
          -  Participants with measurable disease defined as at least one of the following: Serum&#xD;
             M-protein greater than equal to (&gt;=)0.5 gram per deciliter (&gt;=5 gram per liter) or&#xD;
             Urine M-protein &gt;=200 mg per 24 hours or Serum free light chain (FLC) assay: Involved&#xD;
             FLC level &gt;=10 mg per deciliter (&gt;=100 mg per Liter) and an abnormal serum FLC ratio&#xD;
             (&lt;0.26 or &gt;1.65).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with current corneal epithelial disease except mild punctate keratopathy.&#xD;
&#xD;
          -  Participants with evidence of cardiovascular risk&#xD;
&#xD;
          -  Participants with known immediate or delayed hypersensitivity reaction or idiosyncrasy&#xD;
             to drugs chemically related to belantamab mafodotin or any of the components of the&#xD;
             study treatment. History of severe hypersensitivity to other mAb.&#xD;
&#xD;
          -  Participants with active infection requiring antibiotic, antiviral, or antifungal&#xD;
             treatment.&#xD;
&#xD;
          -  Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma&#xD;
             therapy within &lt;14 days.&#xD;
&#xD;
          -  Participants with prior radiotherapy within 2 weeks of start of study therapy.&#xD;
&#xD;
          -  Participants with prior allogeneic transplant are prohibited.&#xD;
&#xD;
          -  Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy&#xD;
             with lymphodepletion with chemotherapy within 3 months of screening.&#xD;
&#xD;
          -  Participants with any major surgery (other than bone-stabilizing surgery) within the&#xD;
             last 30 days.&#xD;
&#xD;
          -  Participants with prior treatment with an investigational agent within 14 days or 5&#xD;
             half-lives of receiving the first dose of study drugs, whichever is shorter.&#xD;
&#xD;
          -  Participants with &gt;=grade 3 toxicity considered related to prior check-point&#xD;
             inhibitors and that led to treatment discontinuation.&#xD;
&#xD;
          -  Participants who have received transfusion of blood products within 2 weeks before the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  Participants must not receive live attenuated vaccines within 30 days prior to first&#xD;
             dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in&#xD;
             any sub-study arm of the platform trial and for at least 70 days following last study&#xD;
             treatment.&#xD;
&#xD;
        Additional Exclusion Criteria for Sub-study 1 and Sub-study 2:&#xD;
&#xD;
          -  Participants with autoimmune disease (current or history) or syndrome that required&#xD;
             systemic treatment within the past 2 years.&#xD;
&#xD;
          -  Exclusion for a recent (within the past 6 months) history of symptomatic pericarditis.&#xD;
&#xD;
        Additional Exclusion Criteria for Sub-study 3:&#xD;
&#xD;
          -  Participants with uncontrolled small and/or large intestinal disease.&#xD;
&#xD;
          -  Participants with uncontrolled skin disease.&#xD;
&#xD;
          -  Participants with any condition causing hypophosphatemia, hypokalemia or&#xD;
             hypomagnesemia which is refractory to electrolyte replacement.&#xD;
&#xD;
          -  Participants with previous administration of a gamma secretase inhibitor.&#xD;
&#xD;
          -  Participants with concomitant administration of a strong or moderate CYP3A4 inhibitor&#xD;
             or inducer.&#xD;
&#xD;
        Additional Exclusion Criteria for Sub-study 4:&#xD;
&#xD;
          -  Participant has an active autoimmune disease that has required systemic treatment in&#xD;
             the past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or&#xD;
             immunosuppressive drugs).&#xD;
&#xD;
          -  Participants who have received prior therapy with an anti-programmed death-1&#xD;
             (anti-PD-1), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2)&#xD;
             agent.&#xD;
&#xD;
          -  Participant has a diagnosis of immunodeficiency or is receiving systemic steroid&#xD;
             therapy or any other form of immunosuppressive therapy within 7 days prior to the&#xD;
             first dose of study treatment. Use of inhaled steroids, local injection of steroids,&#xD;
             and steroid eye drops are allowed.&#xD;
&#xD;
        Additional Exclusion Criteria for Sub-study 5:&#xD;
&#xD;
          -  Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its&#xD;
             excipients.&#xD;
&#xD;
          -  Participants with prior treatment with other anti-CD38 monoclonal antibody within 6&#xD;
             months of the first dose of study drug treatment.&#xD;
&#xD;
          -  Participants with known intolerance or hypersensitivity to infused proteins products,&#xD;
             sucrose, histidine, and polysorbate 80.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ajay Nooka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Attaya Suvannasankha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Richardson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Butler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Natalie Callander</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hang Quach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Routledge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Suzanne Trudel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thierry Facon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent Ribrag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Song-Yau Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katja Weisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jae Hoon Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kihyun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chang Ki Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jae-Cheol Jo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Monique C. Minnema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Rodriguez Otero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Morillo Giles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Rodriguez Otero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pozuelo (Madrid)</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ar√°nzazu Alonso Alonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katarina Uttervall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Belantamab mafodotin</keyword>
  <keyword>GSK2857916</keyword>
  <keyword>GSK3174998</keyword>
  <keyword>Feladilimab</keyword>
  <keyword>Nirogacestat</keyword>
  <keyword>Dostarlimab</keyword>
  <keyword>Isatuximab</keyword>
  <keyword>Platform study</keyword>
  <keyword>Relapsed/Refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

